CPA remains unwavering in our commitment to rebuilding U.S. industry and supporting American workers. China’s latest move only proves that our efforts are making an impact—and we will not back down.
The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on foreign manufacturers for generic drugs is at the center of it.
The Trump administration’s decision to impose a permanent 10% baseline tariff on imports from all countries, combined strategically with higher reciprocal tariffs on nations engaging in unfair trade practices, marks a crucial step forward in reindustrializing America and restoring economic strength and security.
Break out the Grizzly cooler and fire up the Broilmaster—it’s Liberation Day. In President Trump’s words, April 2 marks the end of the US of A being “ripped off by virtually every country in the world.”
The National Institutes of Health (NIH) is today the main source of new drugs in this country – indeed the world, because America leads in the field. It has a critical importance to America’s health. Less well known is its huge, positive, economic impact.
As the United States looks to compete in these advanced industries, it’s important to remember the two building blocks that undergird them: Steel and aluminum.
In a comment letter submitted to USTR in response to the Section 301 investigation, CPA highlighted China’s extensive use of state-driven subsidies and unfair trade practices, urging immediate implementation of targeted measures to support the revitalization of the U.S. shipbuilding industry.
Strong federal investment in the National Science Foundation and National Institutes of Health is vital for American innovation, economic growth, and national security.